Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7806 News 


«12...1213141516171819202122...156157»
  • ||||||||||  Trial completion, Enrollment change:  Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) -  Jun 20, 2017   
    P=N/A,  N=201, Completed, 
    Active, not recruiting --> Completed | N=300 --> 201
  • ||||||||||  Trial termination, Trial primary completion date:  The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) -  Jun 14, 2017   
    P=N/A,  N=973, Terminated, 
    Active, not recruiting --> Completed | Phase classification: P4 --> PN/A Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> May 2017
  • ||||||||||  Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
    Trial primary completion date:  An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA (clinicaltrials.gov) -  Jun 14, 2017   
    P=N/A,  N=950, Recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> May 2017 Trial primary completion date: Sep 2017 --> Dec 2019
  • ||||||||||  Zeposia (ozanimod) / BMS
    Enrollment closed, Enrollment change, Trial primary completion date:  Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS (clinicaltrials.gov) -  Jun 14, 2017   
    P1,  N=6, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=24 --> 6 | Trial primary completion date: Mar 2017 --> Dec 2017
  • ||||||||||  Trial completion, Enrollment change:  Type One Diabetes and Low Carb Study (clinicaltrials.gov) -  Jun 9, 2017   
    P=N/A,  N=340, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Dec 2019 Recruiting --> Completed | N=500 --> 340
  • ||||||||||  Phase classification:  Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes (clinicaltrials.gov) -  Jun 8, 2017   
    P=N/A,  N=124, Active, not recruiting, 
    Trial primary completion date: Nov 2012 --> Mar 2013 Phase classification: P3 --> P=N/A
  • ||||||||||  Enrollment open, Phase classification, Trial initiation date, Trial primary completion date:  Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria (clinicaltrials.gov) -  Jun 7, 2017   
    P,  N=20, Recruiting, 
    Trial primary completion date: Sep 2018 --> Feb 2019 Not yet recruiting --> Recruiting | Phase classification: P1 --> P | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Feb 2017 --> Jul 2018
  • ||||||||||  Enrollment open:  Parents of Young Adults With Type 1 Diabetes: An Exploratory Study (clinicaltrials.gov) -  Jun 7, 2017   
    P=N/A,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: P1 --> P | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Feb 2017 --> Jul 2018 Not yet recruiting --> Recruiting
  • ||||||||||  Enrollment closed, Trial primary completion date:  Open-label Study of Liothyronine in MS (clinicaltrials.gov) -  Jun 5, 2017   
    P1b,  N=20, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Aug 2017
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Trial initiation date, Trial termination:  A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) -  Jun 1, 2017   
    P2,  N=409, Terminated, 
    Recruiting --> Completed Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Enrollment closed, Trial primary completion date:  Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus (clinicaltrials.gov) -  Jun 1, 2017   
    P2,  N=40, Active, not recruiting, 
    Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2018
  • ||||||||||  Byetta (exenatide) / AstraZeneca
    Enrollment open, Trial initiation date:  Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes (clinicaltrials.gov) -  May 31, 2017   
    P2/3,  N=15, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Enrollment open, Trial initiation date, Trial primary completion date:  SURV-SEP: Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (clinicaltrials.gov) -  May 30, 2017   
    P4,  N=250, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Jan 2023 --> Aug 2019
  • ||||||||||  Trial completion:  Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy (clinicaltrials.gov) -  May 30, 2017   
    P2,  N=42, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Jan 2023 --> Aug 2019 Active, not recruiting --> Completed